功能性选择性多巴胺D1受体内细胞和信号由catechol和noncatechol激动剂
Ashley N Nilson1,2, Daniel E Felsing3,2, Pingyuan Wang3,4,2
1Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, Texas 77555-0615, United States.
Biochemistry
|March 20, 2025
概括
新的非catechol多巴胺D1受体 (D1R) 激动剂显示偏差信号,影响受体内细胞化. 均衡的激动因子促进D1R内细胞分裂,而偏向的激动因子没有,揭示了功能选择性.
科学领域:
- 神经药理学神经药理学
- 分子药理学分子药理学
背景情况:
- 多巴胺D1受体 (D1R) 对运动和记忆至关重要,使其成为一种关键的药物标.
- 现有的D1R激动剂由于其甲基醇结构,具有较差的药理动力学.
- 新型非甲基醇D1R激动剂表现出偏差信号,影响受体功能.
研究的目的:
- 调查甲醇和非甲醇D1R激动剂的功能选择性.
- 为了确定偏差信号对D1R内细胞分裂的影响.
- 探索β-arrestin2招募和D1R内细胞分裂之间的关系.
主要方法:
- 评估了各种D1R激动剂的G蛋白和β-arrestin2信号传递.
- 量化激素诱导的D1R内细胞分裂.
- 与D1R内细胞分裂相关联的β-arrestin2招募疗效.
主要成果:
- 大多数非甲基醇D1R激动剂显示G蛋白偏差信号与降低β-arrestin2招募.
- 化合物19显示出平衡的信号传递,而A-77636是一个β-arrestin2超级激素.
- 均衡的激动剂和β-arrestin2超级激动剂诱导了D1R内细胞分裂;G蛋白偏差激动剂没有.
结论:
- D1R激动剂的功能选择性显著影响D1R内细胞分裂,不论药理.
- β-arrestin2招募效率与D1R内细胞分裂的程度有很强的相关性.
- 这些发现为研究D1R信号,贩运和治疗应用提供了有价值的工具.
相关概念视频
Adrenergic Agonists: Indirect-Acting Agents
1.4K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.4K
Drugs Affecting Neurotransmitter Release or Uptake
914
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
914
Adrenergic Agonists: Direct-Acting Agents
1.3K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.3K
Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
Receptor-mediated Endocytosis
5.9K
Receptor-mediated endocytosis is when bulk amounts of specific molecules are imported into a cell after binding to cell surface receptors. The molecules bound to these receptors are taken into the cell through inward folding of the cell surface membrane, which is eventually pinched off into a vesicle within the cell. Structural proteins, such as clathrin, coat the budding vesicle.
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
5.9K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.5K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.5K


